GOSS / Gossamer Bio's stock falls 64% on findings for Phase 2 study for hypertension drug

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercializa more_horizontal

Shares of Gossamer Bio fell Thursday, and the company earned a downgrade from analysts at UBS.  Citing a "lack of near-term catalysts," the firm down more_horizontal

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercializa more_horizontal

Merck's Sotatercept showed significant improvements in PAH patients in Phase 3 STELLAR trial with a primary endpoint of improvements in pulmonary vasc more_horizontal

Gossamer's TORREY showed stat sig PVR improvement, but the 6MWD was under what investors were hoping for; this led to a +70% decline in share price. S more_horizontal

Gossamer Bio (GOSS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). more_horizontal

Gossamer Bio (GOSS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement amo more_horizontal

Gossamer Bio, Inc.'s lead candidate - Seralutinib, indicated for Pulmonary Arterial Hypertension - met its primary endpoint in the Phase 2 TORREY stud more_horizontal